Dr. Kevin FitzGerald has substantial experience of the science and commercial exploitation of drug discovery technologies. Kevin has served as Isogenica's CEO and a main board member of the company since its inception in 2000. During this time, Kevin has completed corporate agreements with ten companies (including Amgen, AstraZeneca, GE Healthcare and Johnson & Johnson) and secured over $7.5m of equity finance. Prior to establishing Isogenica, Kevin was a member of the senior management team at Actinova Ltd., having previously spent seven years at Cambridge Antibody Technology Ltd. where he was among the founding group of scientists. Kevin studied for his Ph.D. in the laboratory of Sir Greg Winter FRS at the MRC Laboratory of Molecular Biology, Cambridge and for his MBA at Aston Business School (awarded with distinction), following receipt of a Sainsbury Management Fellowship from the Royal Academy of Engineering, London.

Renny is Executive Chairman of a clinical research consultancy company working with a number of public and venture capital funded companies developing platform technologies and new clinical treatments for common conditions including cancer. He is a Director of the Phase I resourcing company – iResearch - and is currently a non-executive director of several life science companies as well as one of the top performing NHS Foundation Trusts in England known for its pioneering work in maxillofacial and reconstructive surgery, orthodontics, head and neck cancer and burns. Renny is a Trustee of Lord Snowdon’s Award Scheme for disabled students and clinical research advisor to the charity SPARKS. He was previously CEO of a venture capital backed Clinical Research Organisation, Director of Clinical Research at the Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust and has held senior positions with the UK Medical Research Council and the Horsham-based charity Action Medical Research.

Mr Norfeldt is a psychiatrist and holds a senior position at the Department of Neuropsychiatry, Boras Hospital, Sweden. He has a background in protein chemistry and has performed research on lipoproteins and atherosclerosis. Since 2001 he has also worked as an independent consultant and biotech analyst.

Mr. Lundin brings international experience from VBB AB, EKA Chemicals AB, Berol Verkstadskemi AB (part of the Akzo Nobel group) and, most recently, from Diffchamb AB (publ.), of which Mr Lundin was founder and managing director. Mr Lundin also sits on the board of Dunross, one of Isogenica’s major shareholders.

Professor Leanderson has a medical background as well as a PhD in experimental pathology. He carried out postdoctoral studies at the Basel Institute for Immunology between 1983 and 1986 and was appointed to the Chair of Immunology, Lund University, in 1990. During the last decade he has collaborated with and consulted for a number of pharmaceutical and biotechnology companies. Professor Leanderson is currently Vice President of Research and Development at Active Biotech AB (Lund, Sweden).

Mr Eriksson has an MSc in Economics and more than eighteen years of equity and real estate investment experience. He is a Director of Vasastaden Holding AB and represents one of Isogenica's major shareholders.

Anthony brings over twenty years’ senior management experience to Isogenica. After qualifying as a lawyer in 1979, Anthony held a number of in-house legal positions before his appointment as Vice President Operations and Legal Affairs and Company Secretary at the newly formed Cambridge Antibody Technology, where he took the company from start-up to a full listing on the London Stock Exchange.